📘 Resource Overview & Documentation Details

You are viewing the technical directory listing for Machine Learning for Variant Interpretation in Rare Disease. This engineering resource is curated under our Machine Learning division to support automation specialists, control systems engineers, and manufacturing technicians looking for verified reference materials.

🔍 Contextual Abstract & Technical Scope

Share Summary:LinkedInEmail

Whole-genome sequencing (WGS) and whole-exome sequencing (WES) can reveal extensive genetic variation, but interpreting the resulting data remains a substantial workload. Researchers must filter variants, assess their potential relevance, and review evidence—tasks that require scientific expertise and can involve manual curation. Machine learning variant interpretation tools can help narrow the field, giving analysts a more focused set of candidates to evaluate in rare disease research.

TruSight Software Suite incorporates machine-learning and artificial intelligence tools for variant analysis and prioritization. These tools support parts of the interpretation workflow; they do not remove the need for expert review. Understanding what each tool predicts, and how its results can be investigated, is important when integrating automated prioritization into research workflows.

How machine learning supports variant interpretation

Sequencing can produce millions of variants to consider. Automated filtering and ranking can reduce that initial set to a smaller number of candidates for review. This shifts analyst effort from screening a broad list toward examining the variants and evidence most relevant to a case.

The software suite includes tools that address different parts of this process. SpliceAI predicts the likelihood of splice-related effects, PrimateAI estimates the potential pathogenic impact of missense variants, and Emedgene automates filtering and prioritization of small variants. Their outputs provide different kinds of evidence and should be interpreted in the context of the broader case and available research.

SpliceAI: assessing potential splicing effects

Some variants may affect how pre-messenger RNA is spliced, disrupting the normal processing of genetic information. SpliceAI is a deep residual neural network that uses genomic sequence to predict whether a position may act as a splice donor or acceptor site.

Rather than examining only a short sequence near an exon–intron boundary, SpliceAI evaluates up to 10,000 nucleotides of flanking sequence. This broader sequence context is intended to help identify potential noncoding mutations associated with splicing errors, including cases in which splice sites are separated by substantial genomic distances.

For variants with a SpliceAI score, the score ranges from 0.0 to 1.0 and indicates the predicted likelihood of a splice-site gain or loss. A value closer to 1.0 represents higher confidence in the predicted event. The score is a prediction to consider during interpretation, not a substitute for reviewing the variant and its supporting evidence.

PrimateAI: evaluating missense variants

Missense variants change an amino acid in a protein. PrimateAI uses deep learning to classify mRNA missense variants and predict the likelihood that a variant has a pathogenic effect. Its training approach uses human variant data alongside more than 300,000 unique missense variants collected from six nonhuman primate species.

Using this wider collection of variation was intended to address potential interpretation biases that can arise when training data have limited coverage of the exome. In TruSight Software Suite, the PrimateAI score ranges from 0.0 to 1.0; values closer to 1.0 indicate higher confidence in the prediction of pathogenicity. Analysts can consider this score alongside other information available for a variant and its gene.

Emedgene: ranking candidates and exploring evidence

Emedgene, developed by an Illumina partner, automates portions of variant interpretation. During filtering, it can process small variants, including single nucleotide variants (SNVs) and insertions and deletions (indels), then rank results using a proprietary algorithm. The workflow presents top results as “candidate” or “most likely” variants for review.

To help users understand why a variant is prioritized, Emedgene applies natural language processing (NLP) to data sources and generates a Knowledge Graph for each ranked variant. The graph brings together variant and gene details with associations to clinical indications, including known diseases and confirmed or unconfirmed phenotypes. Links to scientific literature and online databases let users explore supporting information.

This evidence-viewing capability matters because a ranked result needs to be assessed, not simply accepted. Researchers can examine the variant, its gene, and the reported associations to inform follow-up review and curation.

Why reanalysis can change the picture

An example described in the application note illustrates the potential value of revisiting unsolved cases. In 2018, a laboratory analyst received a WGS variant-analysis request involving two unaffected parents and a male proband with neurodevelopmental delay. Initial manual filtering and interpretation did not identify variants associated with known diseases.

After reanalysis a year later with Emedgene, a variant in the TAOK1 gene was prioritized. NLP applied to online databases identified a research article describing de novo TAOK1 variants associated with neurodevelopmental disorders. Review and curation of the called variant and article led to an amended report; the TAOK1 small variant c.557C>T (p.Pro186Leu), heterozygous, was classified as likely pathogenic.

The example highlights how updated information and automated prioritization can bring relevant evidence to an analyst’s attention during reanalysis. Routine manual review of every unsolved case can be difficult to scale, while automated tools can help make systematic reanalysis more practical. The final interpretation still depends on review and curation of the variant and supporting evidence.

Practical considerations for research workflows

  • Use scores as prioritization signals. SpliceAI and PrimateAI provide predictions about specific variant effects; interpret them as part of a broader evidence review.
  • Review the rationale behind rankings. Emedgene’s Knowledge Graph can help users inspect variant, gene, phenotype, and literature associations.
  • Include reanalysis in the workflow. Reassessing unsolved cases may surface relevant findings when new information is available to the analysis tools.
  • Keep expert curation central. Automation can reduce the number of variants requiring initial attention, but scientific review remains essential.

Conclusion

Machine-learning tools can make rare disease sequencing analysis more manageable by filtering and prioritizing variants, predicting possible splice or missense effects, and organizing supporting evidence for review. For research teams, the practical benefit is a more focused starting point for interpretation and a means to support reanalysis of unsolved cases. These outputs should guide, not replace, expert assessment. TruSight Software Suite is designated for research use only and is not intended for diagnostic procedures.

Access Official Technical PDF